


# VICRYL™



08/2019  
0752795  
LA8100434017V2



ar طبخ	fr FIL DE SUTURE
bg КОНЕЦ	hr KIRURŠKI KONAC
cs ŠÍCI MATERIÁL	hu VARRÓANYAG
da SUTUR	it SUTURA
de NAHTMATERIAL	ko 볼합사
el ΡΑΜΜΑ	lt SIŪLAS
en SUTURE	lv KIRURĢISKĀS DIEGS
es SUTURA	mk ХИРУРШКИ КОНЕЦ
et ÖMBLUSMATERJAL	nl HECHTMATERIAAL
fi OMMELAINE	no SUTUR



Johnson & Johnson International  
c/o European Logistics Centre  
Levendastraat 15  
B-1831 Diegem  
Belgium

+1-513-337-6928

## Instructions for use

### VICRYL™ (Polyglactin 910) sterile synthetic absorbable

#### suture

##### DESCRIPTION

VICRYL™ suture is a synthetic absorbable sterile surgical suture composed of a copolymer made from 90% glycolide and 10% L-lactide. The empirical formula of the copolymer is  $(C_6H_{10}O_4)_n(C_6H_{11}O_4)_m$ . Braided VICRYL™ sutures are coated with a mixture composed of equal parts of copolymer of glycolide and lactide (Polyglactin 370) and calcium stearate. Polyglactin 910 copolymer and Polyglactin 370 with calcium stearate have been found to be nonantigenic, nonglycogenic and elicit only a slight tissue reaction during absorption. VICRYL™ sutures are dyed by adding D+C violet #2 (Color Index number: 60725) during polymerisation. Sutures are also available in the undyed form.

VICRYL™ is available in a range of gauge sizes and lengths, non-absorbable or attached to stainless steel needles of varying types and sizes. Note that some sizes of VICRYL™ are available as a monofilament. The needles may be attached permanently or as CR-needle (control release), enabling the needles to be pulled off instead of being cut off. Full details are contained in the catalogue.

VICRYL™ complies with the requirements of the United States Pharmacopoeia for Absorbable Surgical Suture and the European Pharmacopoeia for Sterile Synthetic Absorbable Braided Sutures (except for an occasional slight oversize in some gauges).

##### INDICATIONS

VICRYL™ sutures are intended for use in general soft tissue approximation and/or ligation, including use in ophthalmic surgery, peripheral nerve anastomosis and microsurgery for vessels less than 2 mm diameter. The safety and effectiveness of VICRYL™ sutures in cardiovascular tissue have not been established.

##### APPLICATION

Sutures should be selected and implanted depending on patient condition, surgical experience, surgical technique and wound size.

##### PERFORMANCE

VICRYL™ suture elicits a minimal initial inflammatory reaction in tissues and ingrowth of fibrous connective tissue. Progressive loss of tensile strength and eventual absorption of VICRYL™ sutures occurs by means of hydrolysis, where the copolymer degrades to glycolic and lactic acids which are subsequently absorbed and metabolized in the body. Absorption begins as a loss of tensile strength followed by a loss of mass. All of the original tensile strength is lost by five weeks post implantation. Absorption of VICRYL™ suture is essentially complete between 56 and 70 days.

## en

Days	Approximate % original Strength Remaining
Implantation	75%
14 days	50%
21 days [6-0 and larger]	40%
21 days [7-0 and smaller]	40%
28 days [6-0 and larger]	25%

##### CONTRAINDICATIONS

These sutures, being absorbable should not be used where extended approximation of tissues under stress is required.

##### WARNINGS/PRECAUTIONS/INTERACTIONS

Users should be familiar with surgical procedures and techniques involving absorbable sutures before employing VICRYL™ suture for wound closure, as risk of wound dehiscence may vary with the site of application and the suture material used. Surgeons should consider the *in vivo* performance (under PERFORMANCE section) when selecting a suture.

As with any foreign body, prolonged contact of any suture with salt solutions, such as those found in the urinary or biliary tracts, may result in calculus formation. As an absorbable suture VICRYL™ may act transiently as a foreign body.

Acceptable surgical practice should be followed for the management of contaminated or infected wounds.

As this is an absorbable suture material, the use of supplemental nonabsorbable sutures should be considered by the surgeon in the closure of the sites which may undergo expansion, stretching or distension, or which may require additional support. Skin sutures which must remain in place longer than 7 days may cause localised irritation and should be snipped off or removed as indicated.

Under some circumstances, notably orthopaedic procedures, immobilisation of joints by external support may be employed at the discretion of the surgeon.

Consideration should be taken in the use of absorbable sutures in tissues with poor blood supply as suture extrusion and delayed absorption may occur. Subcuticular sutures should be placed deeply as possible to minimize the erythema and induration normally associated with the absorption process.

This suture may be inappropriate in elderly, malnourished or debilitated patients, or in patients suffering from conditions which may delay wound healing. When handling this or any other suture material, care should be taken to avoid damage. Avoid crushing or crimping damage due to application of surgical instruments such as forceps or needle holders.

Care should be taken to avoid damage when handling surgical needles. Grasp the needle in an area one-third (1/3) to one-half (1/2) of the distance from the attachment end to the point. Grasping in the point area could impair the penetration performance and cause fracture of the needle. Grasping at the butt or attachment end could cause bending or breakage. Reshaping needles may cause them to lose strength and be less resistant to bending and breaking. All needles are magnetizable and should therefore not be used in an active magnetic field.

Users should exercise caution when handling surgical needles to avoid inadvertent needle stick injury. Discard used needles in 'Sharps' containers.

Adequate knot security requires the standard surgical technique of flat and square ties with additional throws as indicated by surgical circumstances and the experience of the surgeon. The use of additional throws may be particularly appropriate when knotting any monofilament suture.

Do not resterilize/reuse. Reuse of this device (or portions of this device) may create a risk of product degradation and cross-contamination, which may lead to infection or transmission of bloodborne pathogens to patients and users.

##### ADVERSE REACTIONS

Adverse reactions associated with the use of this device include transitory local irritation at the wound site, transitory inflammatory foreign body response, erythema and induration during the absorption process of subcuticular sutures. Like all foreign bodies VICRYL™ may potentiate an existing infection.

##### STERILITY

VICRYL™ sutures are sterilized by ethylene oxide gas. Do not resterilize Do not use if package is opened or damaged! Discard opened, unused sutures!

##### STORAGE

No special storage conditions required. Do not use after expiry date!

##### SYMBOLS USED ON LABELLING

- = Do not reuse
- = Number of units
- = Use by – year and month

**STERILE EO** = Sterile unless package is damaged or opened  
Method of sterilization: Ethylene Oxide

**CE** 2797 = CE-mark and identification number of Notified Body.  
= The product meets the essential requirements of Medical Device Directive 93/42/EEC

- LOT** = Batch number
- = Caution: See instructions for use
- = Manufacturer
- REF** = Catalogue Number